JPH11514650A - 治療用シスプラチン(cddp)のための改良された方法及び組成物 - Google Patents
治療用シスプラチン(cddp)のための改良された方法及び組成物Info
- Publication number
- JPH11514650A JPH11514650A JP9517640A JP51764097A JPH11514650A JP H11514650 A JPH11514650 A JP H11514650A JP 9517640 A JP9517640 A JP 9517640A JP 51764097 A JP51764097 A JP 51764097A JP H11514650 A JPH11514650 A JP H11514650A
- Authority
- JP
- Japan
- Prior art keywords
- cisplatin
- cddp
- suspension
- gel
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約0.05〜0.75%の非イオン性界面活性剤;及び 約2〜8mg/mlのシスプラチン、 を含んで成るシスプラチンの安定した水性分散液。 2.約0.05〜0.75%の非イオン性界面活性剤; 約2〜8mg/mlのシスプラチン、 を水性ビークルに含んで成る、患者における腫瘍性病巣へのシスプラチンの供給 のために有用な配合物。 3.約0.5〜8.0%のコラーゲンをさらに含んで成る請求の範囲第2項記載の配 合物。 4.約0.01%〜0.25%のカルボキシメチルセルロースナトリウムをさらに含ん で成る請求の範囲第2又は3項記載の配合物。 5.前記非イオン性界面活性剤がポリソルベートである請求の範囲第2項記載 の配合物。 6.前記ポリソルベートがポリソルベート80である請求の範囲第5項記載の配 合物。 7.約0.02〜0.2mg/mlのエピネフリンをさらに含んで成る請求の範囲第3項 記載の配合物。 8.約0.05〜0.75%のポリソルベート80; 約0.05〜0.2mg/mlのエピネフリン; 約1.5〜6.5mg/mlのCDDP; 約0.5〜8.0%のコラーゲン、 を水性ビークルに含んで成る、患者における腫瘍性病巣へのシスプラチンの供給 のために有用な配合物。 9.約0.01%〜0.25%のカルボキシメチルセルロースナトリウムをさらに含ん で成る請求の範囲第8項記載の配合物。 10.患者における腫瘍性病巣の処理のためのシスプラチン配合物の調製方法で あって、 約0.05〜0.75%の非イオン性界面活性剤を含んで成る水性希釈剤に凍結乾燥さ れたシスプラチンを再懸濁し、約2〜8mg/mlのシスプラチンの懸濁液を形成す ることを含んで成る方法。 11.約0.5〜8.0%のコラーゲンを含む水性ゲルをもたらすために、前記懸濁液 とコラーゲンゲルとを混合する段階をさらに含んで成る請求の範囲第7項記載の 方法。 12.前記非イオン性界面活性剤がポリソルベートである請求の範囲第7項記載 の方法。 13.前記ポリソルベートがポリソルベート80である請求の範囲第9項記載の方 法。 14.前記希釈剤が約0.02〜0.2mg/mlのエピネフリンをさらに含んで成る請求 の範囲第10項記載の方法。 15.治療用シスプラチン懸濁液の調製のためのキットであって、 凍結乾燥されたシスプラチン; 約0.05〜0.75%のポリソルベート80及び約0.02〜0.2mg/mlのエピネフリンを 含んで成る、前記シスプラチンの懸濁のための水性希釈剤、を含んで成るキット 。 16.コラーゲンゲルをさらに含んで成る請求の範囲第12項記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/550,086 US6077545A (en) | 1995-10-30 | 1995-10-30 | Process and composition for therapeutic cisplatin (CDDP) |
US08/550,086 | 1995-10-30 | ||
PCT/US1996/018525 WO1997016196A1 (en) | 1995-10-30 | 1996-10-29 | Improved process and composition for therapeutic cisplatin (cddp) |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11514650A true JPH11514650A (ja) | 1999-12-14 |
Family
ID=24195686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9517640A Ceased JPH11514650A (ja) | 1995-10-30 | 1996-10-29 | 治療用シスプラチン(cddp)のための改良された方法及び組成物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US6077545A (ja) |
EP (1) | EP0861084B1 (ja) |
JP (1) | JPH11514650A (ja) |
KR (1) | KR100486146B1 (ja) |
AT (1) | ATE219370T1 (ja) |
AU (1) | AU722687B2 (ja) |
DE (1) | DE69621942T2 (ja) |
DK (1) | DK0861084T3 (ja) |
ES (1) | ES2177817T3 (ja) |
PT (1) | PT861084E (ja) |
WO (1) | WO1997016196A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6722054B2 (en) | 1998-11-12 | 2004-04-20 | Atrix Laboratories, Inc. | Process and delivery container for lyophilizing active agent |
US6907679B2 (en) * | 1998-11-12 | 2005-06-21 | Qlt Usa, Inc. | Method for lyophilizing an active agent |
WO2000038672A2 (en) | 1998-12-23 | 2000-07-06 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
IN186588B (ja) * | 1999-07-28 | 2001-10-06 | Vinod Daftary Gautam Dr | |
US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US6566144B1 (en) * | 2000-03-27 | 2003-05-20 | Atrix Laboratories | Cover plate for use in lyophilization |
IL160960A0 (en) * | 2001-09-24 | 2004-08-31 | Tosk Inc | Reduced toxicity cisplatin formulations and methods for using the same |
US9266785B2 (en) | 2001-12-20 | 2016-02-23 | Zero Gravity Solutions, Inc. | Bioavailable minerals for plant health |
US20120171130A1 (en) * | 2001-12-20 | 2012-07-05 | John Wayne Kennedy | Mitigation of Animal and Plant Diseases Using Bioavailable Minerals |
US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
BR0313060A (pt) * | 2002-07-29 | 2005-06-28 | Transform Pharmaceuticals Inc | Composições farmacêuticas aquosas de 2,6-diisopropilfenol |
US20100035853A1 (en) * | 2008-08-07 | 2010-02-11 | Hyogo College Of Medicine | Method for preventing or treating cisplatin-induced nephrotoxicity |
WO2010139752A2 (en) | 2009-06-04 | 2010-12-09 | Alk Ag | Stabilised composition comprising at least one adrenergic compound |
US8628805B2 (en) * | 2009-06-04 | 2014-01-14 | Alk Ag | Stabilized composition comprising at least one adrenergic compound |
US10794632B2 (en) | 2016-02-05 | 2020-10-06 | Tolmar Therapeutics, Inc. | Vented cover plate for an array of syringes |
EP3677283A4 (en) * | 2017-08-31 | 2021-05-12 | Tohoku University | APPROPRIATE AREA OF OSMOTIC PRESSURE OF A SOLUTION WITH MEDICINAL PRODUCT EFFECTIVE IN LYMPHODIC DELIVERY SYSTEM |
US11241586B2 (en) | 2017-10-10 | 2022-02-08 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia |
WO2019072723A1 (en) | 2017-10-10 | 2019-04-18 | Merck Patent Gmbh | STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS OF L-EPINEPHRINE |
USD908916S1 (en) | 2018-06-19 | 2021-01-26 | Tolmar Therapeutics, Inc. | Syringe restrictor plate |
EP3586823A1 (en) | 2018-06-25 | 2020-01-01 | CAPNOMED GmbH | Therapeutic composition, method and set for providing said therapeutic composition |
US20220354794A1 (en) | 2019-09-20 | 2022-11-10 | Nivagen Pharmaceuticals, Inc. | Lyophilized Compositions of Phenobarbital Sodium Salt |
US11406598B2 (en) * | 2019-09-20 | 2022-08-09 | Nivagen Pharmaceuticals, Inc. | Lyophilized compositions of phenobarbital sodium salt |
WO2021216957A1 (en) * | 2020-04-23 | 2021-10-28 | Massachusetts Institute Of Technology | Systems, devices, and methods for gamma entrainment using sensory stimuli to alleviate cognitive deficits and/or neuroinflammation induced by chemotherapy agents |
CN113995714B (zh) * | 2021-10-28 | 2023-04-28 | 杭州师范大学 | 一种顺铂交联的蛋白水凝胶及制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619913A (en) * | 1984-05-29 | 1986-10-28 | Matrix Pharmaceuticals, Inc. | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
US5100877A (en) * | 1986-05-21 | 1992-03-31 | Kuraray Co., Ltd. | Platinum containing pullulan derivatives and pharmaceutical compositions comprising the same |
DK86988A (da) * | 1987-02-25 | 1988-08-26 | Takeda Chemical Industries Ltd | Liposompraeparat og anvendelse deraf |
EP0464210A4 (en) * | 1989-12-15 | 1992-11-25 | Tsumura & Co. | Novel platinum complex and antitumor drug containing the same as active ingredient |
NL9000634A (nl) * | 1990-03-20 | 1991-10-16 | Catharina Ziekenhuis Stichting | Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding. |
US5750146A (en) * | 1995-04-28 | 1998-05-12 | Matrix Pharmaceutical, Inc. | Translucent collagen formulations with a cytotoxic drug |
-
1995
- 1995-10-30 US US08/550,086 patent/US6077545A/en not_active Expired - Fee Related
-
1996
- 1996-10-29 JP JP9517640A patent/JPH11514650A/ja not_active Ceased
- 1996-10-29 DE DE69621942T patent/DE69621942T2/de not_active Expired - Fee Related
- 1996-10-29 AU AU76820/96A patent/AU722687B2/en not_active Ceased
- 1996-10-29 WO PCT/US1996/018525 patent/WO1997016196A1/en active IP Right Grant
- 1996-10-29 DK DK96939733T patent/DK0861084T3/da active
- 1996-10-29 ES ES96939733T patent/ES2177817T3/es not_active Expired - Lifetime
- 1996-10-29 EP EP96939733A patent/EP0861084B1/en not_active Expired - Lifetime
- 1996-10-29 PT PT96939733T patent/PT861084E/pt unknown
- 1996-10-29 AT AT96939733T patent/ATE219370T1/de not_active IP Right Cessation
- 1996-10-29 KR KR10-1998-0703159A patent/KR100486146B1/ko not_active IP Right Cessation
-
1998
- 1998-01-26 US US09/013,568 patent/US6224883B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6077545A (en) | 2000-06-20 |
EP0861084A4 (en) | 2000-02-02 |
EP0861084A1 (en) | 1998-09-02 |
ES2177817T3 (es) | 2002-12-16 |
AU7682096A (en) | 1997-05-22 |
PT861084E (pt) | 2002-11-29 |
ATE219370T1 (de) | 2002-07-15 |
DK0861084T3 (da) | 2002-10-07 |
DE69621942T2 (de) | 2003-01-23 |
EP0861084B1 (en) | 2002-06-19 |
KR100486146B1 (ko) | 2005-08-05 |
AU722687B2 (en) | 2000-08-10 |
KR20000064302A (ko) | 2000-11-06 |
DE69621942D1 (de) | 2002-07-25 |
WO1997016196A1 (en) | 1997-05-09 |
US6224883B1 (en) | 2001-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11514650A (ja) | 治療用シスプラチン(cddp)のための改良された方法及び組成物 | |
TWI292716B (en) | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles | |
US20070077286A1 (en) | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | |
CA2371912A1 (en) | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | |
TW200526252A (en) | Surfactant-based gel as an injectable, sustained drug delivery vehicle | |
EP1274459A2 (en) | Sustained release formulations comprising growth hormone | |
AU2001259111A1 (en) | Sustained release formulations comprising growth hormone | |
JPH06510772A (ja) | 固体状脂質微粒子(固体状脂質ナノ球体)製の薬剤用キャリヤー | |
JP2014533740A (ja) | 疎水性薬物送達材料、その製造方法および薬物送達組成物の送達方法 | |
JP2002348234A (ja) | 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤 | |
KR20100127267A (ko) | 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액 | |
ES2637379T3 (es) | Material polimérico de administración de fármacos, método para fabricar el mismo y método para la administración de una composición de administración de fármacos | |
KR20150114505A (ko) | 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형 | |
JP2003508436A (ja) | 非経口投与のための医薬として安定なオキザリプラチナム製剤 | |
WO2016177346A1 (zh) | 一种卡巴他赛脂肪乳注射剂及其制备方法和用途 | |
CN109316440A (zh) | 一种温敏性液晶纳米水凝胶及其制备方法与应用 | |
KR890000907B1 (ko) | 안정한 현탁액 제조용 고체 약물 제형의 제조방법 | |
US20210379083A1 (en) | Pharmaceutical composition and use | |
CN1511037A (zh) | 非肠道使用的雌莫司汀磷酸盐和白蛋白的制剂 | |
EA003936B1 (ru) | Препараты эстрамустинфосфата и сульфоалкиловых эфиров циклодекстринов для парентерального применения | |
CN1177583C (zh) | 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂 | |
CA2236207A1 (en) | Improved process and composition for therapeutic cisplatin (cddp) | |
CN102389571B (zh) | 一种可体内注射的药物缓释栓剂 | |
CN116262100A (zh) | 一种氟维司群凝胶组合物及其制备方法和应用 | |
CN103127514B (zh) | 一种可体内注射的药物缓释栓剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070808 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20080219 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20080401 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20080219 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20080219 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20080219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090120 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090511 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090623 |